C. Makepeace - Biogen | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 17 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

CO108 Longitudinal Trends in Hospitalization Rates in Patients with Later-Onset Spinal Muscular Atrophy (SMA) Treated with Nusinersen Up to 4.5 Years: Results from the Cherish and Shine Studies

T. Jiang,B. Darras,B. Youn,C. Makepeace,R. Chin,Z. Berger,S. Raynaud,A. D. Paradis, N. Johnson

Value in healthno. 6 (2023): S34-S35

引用0浏览0引用

P210 Interim Results from the RESPOND Study Evaluating Nusinersen in Children with Spinal Muscular Atrophy Previously Treated with Onasemnogene Abeparvovec

J. Parsons,N. Kuntz,J. Brandsema,C. Proud,R. Finkel,K. Swoboda,R. Masson,R. Foster,Y. Liu,C. Makepeace, S. Singhi,A. Paradis,Z. Berger, S. Rane,K. Somera-Molina

Neuromuscular Disorders (2023): S87-S87

引用0浏览0引用

Swallowing Function in Children with Later-Onset Spinal Muscular Atrophy Treated with Nusinersen: CHERISH-SHINE Results

F. Muntoni,T. Crawford,D. Castro,M. Scoto, C. Zhu,C. Makepeace,Z. Berger,R. Chin,S. Raynaud,A. Paradis

EUROPEAN JOURNAL OF NEUROLOGY（2022）

引用0浏览0引用

P.101 Baseline Characteristics/initial Safety in RESPOND: Phase 4 Study of Nusinersen in Children with SMA Who Previously Received Onasemnogene Abeparvovec

C. Proud,J. Parsons,R. Masson,J. Brandsema,R. Finkel,K. Swoboda,E. Finanger,Y. Liu,C. Makepeace,A. Paradis,Z. Berger, J. Wagner,K. Somera-Molina

Neuromuscular Disorders (2022): S86-S86

引用0浏览0引用

FP.22 Results from the End of Part A of the Ongoing 3-Part DEVOTE Study to Explore Higher Doses of Nusinersen in SMA

J. Day,R. Finkel,S. Pascual,M. Ryan,E. Mercuri,D. De Vivo,J. Montes,J. Gurgel-Giannetti,G. Gambino,C. Makepeace,R. Foster, V. Irzhevsky,Z. Berger

NEUROMUSCULAR DISORDERS (2022): S85-S85

引用1浏览0引用

Preserved Swallowing Function In Infants Who Initiated Nusinersen Treatment In The Presymptomatic Stage Of Sma: Results From The Nurture Study

V. Sansone,K. Swoboda,D. De Vivo,E. Bertini,W. Hwu,C. Makepeace,J. Bohn,R. Chin,S. Raynaud,A. Paradis

NEUROMUSCULAR DISORDERS（2021）

引用0浏览0引用

Longer-term Safety Data in Individuals with Later-onset SMA Support the Favourable Tolerability Profile of Nusinersen

M. Farrar,D. Castro,R. Finkel,M. Tulinius,K. Saito,K. Krosschell,R. Foster,S. Garafalo,A. Paradis,C. Makepeace

EUROPEAN JOURNAL OF NEUROLOGY（2021）

引用2浏览0引用

Nusinersen In Children With Spinal Muscular Atrophy (Sma) Who Received Onasemnogene Abeparvovec: Design Of The Phase 4, Open-Label Respond Study

C. Proud,J. Parsons,J. Brandsema,R. Finkel,K. Swoboda,R. Foster,C. Makepeace,A. Paradis,Z. Berger,K. Somera-Molina

NEUROMUSCULAR DISORDERS（2021）

引用0浏览0引用

Escalating Dose and Randomized, Controlled Study of Nusinersen in Participants with Spinal Muscular Atrophy (SMA); Study Design and Part A Data for the Phase 2/3 DEVOTE (232SM203) Study to Explore High Dose Nusinersen (2343)

John W. Day, Pascual,Richard S. Finkel,Monique M. Ryan,Eugenio Mercuri,Darryl C. De Vivo,Jacqueline Montes,Juliana Gurgel‐Giannetti,Giulia Gambino, Rebecca Nuzzo,C. Makepeace,Zdenek Berger

Neurologyno. 15_supplement (2021)

引用0浏览0引用

SMA - TREATMENT: EP.271 Part A results from the ongoing DEVOTE study to explore higher-dose nusinersen in SMA

E. Mercuri,R. Finkel,J. Day,S. Pascual Pascual, M. Ryan,D. De Vivo,J. Montes,J. Gurgel-Giannetti,G. Gambino, R. Nuzzo,C. Makepeace,S. Garafalo,Z. Berger

Neuromuscular Disorders (2021): S132

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn